Diabetes & Endocrinology

Navigating the Frontiers of Premature Ovarian Insufficiency Research: Insights from the Top 100 Influential Articles

By MedXY 10/22/2025

A comprehensive bibliometric analysis of the 100 most-cited articles in premature ovarian insufficiency reveals key research trends, leading contributors, and emerging scientific directions in genetics, cardiovascular disease, and immunology.

Diabetes & Endocrinology HIV/AIDS Internal Medicine Specialties

Nucleoside Reverse Transcriptase Inhibitors: A Novel Therapeutic Avenue Against Inflammaging and Age-Related Diseases

By MedXY 10/22/2025

NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.

Diabetes & Endocrinology Psychiatry Specialties

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY 10/22/2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychiatric symptoms.

Diabetes & Endocrinology news Public Health

Leveraging the Planetary Health Diet to Reduce Type 2 Diabetes Risk and Environmental Impact: Insights from the EPIC-Norfolk Study

By MedXY 10/20/2025

Higher adherence to the planetary health diet is linked with a 32% reduced risk of type 2 diabetes and significantly lower greenhouse gas emissions, supporting its role in preventing diabetes and promoting sustainability.

Diabetes & Endocrinology Family Medicine & Nutrition Public Health Specialties

Planetary Health and Plant-Based Diets: Reducing Type 2 Diabetes Risk in UK Adults

By MedXY 10/20/2025

Higher adherence to the Planetary Health Diet Index, reflecting environmentally sustainable plant-based eating patterns, is strongly associated with reduced type 2 diabetes risk in UK Biobank participants, comparable or superior to other established plant-based diet scores.

Cardiology Diabetes & Endocrinology news

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

By MedXY 10/19/2025

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes status.

Cardiology Diabetes & Endocrinology Specialties

Triglyceride Glucose-Waist Height Ratio Index as a Predictor of Cardiometabolic Multimorbidity in Chinese Middle-Aged and Older Adults: Insights from a National Prospective Cohort Study

By MedXY 10/19/2025

This study demonstrates that the triglyceride glucose-waist height ratio (TyG-WHtR) index independently predicts cardiometabolic multimorbidity risk in Chinese adults aged ≥45, showing a linear dose-response relationship and improved predictive performance over traditional metrics.

Cardiology Diabetes & Endocrinology news

Joint Impact of TyG-Related Indices and eGDR on Cardiometabolic Multimorbidity Risk in Chinese Adults: Insights from a Nationwide Cohort

By MedXY 10/19/2025

This study elucidates that high triglyceride glucose (TyG) related indices combined with low estimated glucose disposal rate (eGDR) synergistically elevate cardiometabolic multimorbidity (CMM) risk in middle-aged and older Chinese adults, enhancing early risk stratification and prevention strategies.

Cardiology Diabetes & Endocrinology Nephrology news

Insulin Resistance Indices as Predictors of Cardio-Renal-Metabolic Multimorbidity: Insights from the UK Biobank

By MedXY 10/19/2025

This study demonstrates that insulin resistance indices, particularly TyG-WC, TyG-WHtR, and METS-IR, robustly predict the risk and progression of cardio-renal-metabolic multimorbidity, with inflammation and kidney function mediating these associations.

Diabetes & Endocrinology Nephrology Specialties

Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort

By MedXY 10/19/2025

This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.

Diabetes & Endocrinology Internal Medicine Specialties

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

By MedXY 10/19/2025

This review examines a landmark Peruvian study applying new obesity definitions that incorporate clinical dysfunction and adiposity measures beyond BMI, revealing substantial underdiagnosis with traditional approaches and ethnic variation in fat distribution.

Diabetes & Endocrinology General Surgery news

Long-Term Comparative Outcomes of Gastric Bypass and Sleeve Gastrectomy in Type 2 Diabetes: Evidence from a Swedish Matched Cohort Study

By MedXY 10/19/2025

A Swedish nationwide study reveals Roux-en-Y gastric bypass yields superior long-term benefits in type 2 diabetes remission and reduced mortality compared to sleeve gastrectomy, despite higher risks of nutritional deficiencies and psychiatric complications.

Diabetes & Endocrinology news Public Health Specialties

Bridging the Gaps in Global Diabetes Care: Insights from Two Decades of the Global Burden of Disease Study

By MedXY 10/19/2025

A comprehensive analysis reveals ongoing challenges in diabetes diagnosis, treatment, and glycaemic control worldwide, highlighting the urgent need for enhanced care strategies, especially in low- and middle-income regions.

Diabetes & Endocrinology Specialties

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY 10/18/2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Diabetes & Endocrinology Internal Medicine Specialties

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

By MedXY 10/18/2025

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Diabetes & Endocrinology news Oncology

Enhancing Prognostication in Papillary Thyroid Cancer: Integrating BRAF and TERT Mutations into the AJCC Staging System

By MedXY 10/15/2025

Incorporating BRAF and TERT promoter mutations into the AJCC classification for papillary thyroid cancer significantly improves mortality risk prediction, refining patient stratification beyond traditional clinical staging.

Diabetes & Endocrinology Ophthalmology Specialties

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY 10/15/2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Diabetes & Endocrinology news Urology

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

By MedXY 10/12/2025

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits from surgical weight loss.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Evaluating Selenium Supplementation in Gestational Diabetes Mellitus: Insights from a Systematic Review and Meta-Analysis

By MedXY 10/12/2025

Selenium supplementation at 200 µg/d may reduce fasting plasma glucose and newborn hyperbilirubinemia risk in gestational diabetes without significantly altering lipid profiles, highlighting potential but limited benefits requiring further research.

Diabetes & Endocrinology Specialties

Optimizing Antithymocyte Globulin Dose for Preserving Beta-Cell Function in Recent-Onset Type 1 Diabetes: Insights from the MELD-ATG Trial

By MedXY 10/11/2025

The MELD-ATG phase 2 trial identifies low-dose antithymocyte globulin as an effective and safe intervention to reduce beta-cell loss in young people with recent-onset type 1 diabetes, highlighting a potential disease-modifying therapy.